Dicerna Pharmaceuticals (DRNA) Earns Neutral Rating from Chardan Capital

Chardan Capital reiterated their neutral rating on shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) in a research note released on Tuesday morning.

Other research analysts have also recently issued research reports about the stock. Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a strong sell rating to a buy rating and set a $6.25 price objective for the company in a report on Monday, October 23rd. HC Wainwright restated a buy rating and issued a $10.00 price objective (up previously from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. BidaskClub cut shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, January 9th. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a sell rating to a hold rating in a report on Sunday, December 31st. Finally, Evercore ISI initiated coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday. They issued an outperform rating and a $14.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Dicerna Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $8.25.

Shares of Dicerna Pharmaceuticals (NASDAQ DRNA) traded down $0.14 during mid-day trading on Tuesday, hitting $8.83. 162,162 shares of the company were exchanged, compared to its average volume of 335,321. The firm has a market capitalization of $448.88, a PE ratio of -2.57 and a beta of 2.84. Dicerna Pharmaceuticals has a 52-week low of $2.42 and a 52-week high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The business’s quarterly revenue was up 192.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.68) EPS. sell-side analysts expect that Dicerna Pharmaceuticals will post -2.93 earnings per share for the current year.

In other news, Director Bain Capital Life Sciences Inv purchased 285,000 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The stock was bought at an average price of $7.00 per share, for a total transaction of $1,995,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 29.41% of the stock is owned by insiders.

A number of institutional investors have recently modified their holdings of DRNA. EcoR1 Capital LLC lifted its stake in Dicerna Pharmaceuticals by 101.0% in the second quarter. EcoR1 Capital LLC now owns 767,992 shares of the biopharmaceutical company’s stock worth $2,435,000 after acquiring an additional 385,992 shares during the last quarter. Deschutes Portfolio Strategy LLC purchased a new position in Dicerna Pharmaceuticals in the third quarter worth approximately $575,000. Birchview Capital LP lifted its stake in Dicerna Pharmaceuticals by 125.0% in the third quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after acquiring an additional 25,000 shares during the last quarter. Palo Alto Investors LLC lifted its stake in Dicerna Pharmaceuticals by 4.0% in the second quarter. Palo Alto Investors LLC now owns 500,913 shares of the biopharmaceutical company’s stock worth $1,588,000 after acquiring an additional 19,394 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Dicerna Pharmaceuticals by 4.5% in the second quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after acquiring an additional 14,517 shares during the last quarter. Institutional investors own 21.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Dicerna Pharmaceuticals (DRNA) Earns Neutral Rating from Chardan Capital” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3147896/dicerna-pharmaceuticals-drna-earns-neutral-rating-from-chardan-capital.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Analyst Recommendations for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.